Cidara's core technology attaches potent small-molecule drugs to an inert antibody fragment. This design extends a drug's presence in the body while preventing it from entering human cells. This reduces the off-target toxicities common in high-dose treatments, a principle the company is applying to both its flu preventative and cancer therapies.

Unlike existing drugs that act as "molecular glues" causing broad tissue toxicity, LifeMine's inhibitor uses a different mechanism. It prevents enzyme activation and has superior biodistribution, staying concentrated in the blood where it's needed, thus dramatically improving the safety profile.

Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.

In the race to treat Friedreich's Ataxia, the choice of viral vector is a key competitive differentiator. While most use AAVs, some companies use HSV vectors for larger payload capacity or engineered AAV capsids to cross the blood-brain barrier. This highlights that the delivery system's innovation is as critical as the therapeutic gene itself.

The historical difficulty of delivering biologics to the brain is being addressed by novel "brain shuttle" technologies. These platforms, which facilitate transport across the blood-brain barrier, are enabling new enzyme replacement therapies and even AAV-delivered biologics for CNS diseases like leukodystrophies.

Bio Arctic is applying its successful Alzheimer's playbook to Parkinson's disease. This involves a highly selective compound that targets only the toxic protein aggregates (alpha-synuclein) while sparing healthy forms, combined with ensuring patients with the correct pathology are selected for trials.

Mini-proteins are framed as a superior drug modality that merges the key strengths of traditional therapies. They possess the high selectivity characteristic of biologics like antibodies, while also having the stability and formulation advantages of small-molecule drugs. This combination allows them to precisely target difficult receptors while avoiding common off-target effects or instability issues.

The challenge of getting drugs into the brain is being solved, as proven by Denali's recent FDA approval for a drug using its BBB shuttle for Hunter disease. This, combined with Roche's promising Alzheimer's data with a similar technology, provides hard evidence that these platforms work, driving significant M&A and investment activity.

Voyager CEO Al Sandrock explains their AAV capsids are engineered to be so potent at crossing the blood-brain barrier that doses can be an order of magnitude lower than standard. Crucially, the capsids are also designed to *avoid* the liver, directly addressing the toxicity issues that have plagued the field.